	US 11,965,893 B2
	Biomarker for preeclampsia
Chris Watson, Belfast (GB); Timothy Lyons, Belfast (GB); Alice Cheung, Belfast (GB); and Clare Kelly, Belfast (GB)
Assigned to The Queen's University of Belfast, Belfast (GB)
Filed by The Queen's University of Belfast, Belfast (GB)
Filed on Jul. 7, 2022, as Appl. No. 17/811,167.
Application 17/811,167 is a continuation of application No. 16/487,179, abandoned, previously published as PCT/EP2018/054194, filed on Feb. 21, 2018.
Claims priority of application No. 1702792 (GB), filed on Feb. 21, 2017.
Prior Publication US 2023/0133540 A1, May 4, 2023
Int. Cl. G01N 33/68 (2006.01); C07K 16/18 (2006.01)

CPC G01N 33/689 (2013.01) [C07K 16/18 (2013.01); C07K 2317/34 (2013.01); G01N 2333/471 (2013.01); G01N 2800/368 (2013.01); G01N 2800/50 (2013.01)]

10 Claims

1. An in vitro method of processing a biological sample from a pregnant subject at risk of developing a hypertensive disorder of pregnancy, the method comprising:

obtaining a biological sample from the pregnant subject at risk of developing a hypertensive disorder of pregnancy, and

detecting a level of leucine-rich alpha 2 glycoprotein 1 (LRG1) in said biological sample from said pregnant subject.